• Citer

Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT).

par Loi, Sherene ;Savas, P;Lönnstedt, Ingrid IM;Fumagalli, Debora ;Caramia, Franco;Li, J;Salgado, Roberto;Rowan, Andrew;Andre, Fabrice;Denkert, Carsten;Neven, P;Loibl, Sibylle;Sotiriou, Christos ;Swanton, Charles;Speed, Terence P
Référence San Antonio Breast Cancer Symposium – SABCS (December 11, 2014: San Antonio, Tx, USA)
Publication Non publié, 2014-12

Poster de conférence

• Détails

Titre:	Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT).
Auteur:	Loi, Sherene; Savas, P; Lönnstedt, Ingrid IM; Fumagalli, Debora; Caramia, Franco; Li, J; Salgado, Roberto; Rowan, Andrew; Andre, Fabrice; Denkert, Carsten; Neven, P; Loibl, Sibylle; Sotiriou, Christos; Swanton, Charles; Speed, Terence P
Informations sur la publication:	San Antonio Breast Cancer Symposium – SABCS (December 11, 2014: San Antonio, Tx, USA)
Statut de publication:	Non publié, 2014-12
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Langue:	Anglais